This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	Adhesion regulating molecule 1 (ADRM1; RPN13)	<p><i>In vitro</i> and mouse studies suggest inhibiting the RPN13 proteasomal component could help treat cancer. <i>In vitro</i>, a <i>bis</i>-benzylidene piperidone bound to the pleckstrin-like receptor for ubiquitin domain of RPN13. In cancer cell lines, the compound induced accumulation of polyubiquitinated proteins and apoptosis at a rate similar to or faster than Velcade bortezomib. In mouse models of multiple myeloma, ovarian cancer and human papilloma virus-related cancer, the compound inhibited tumor growth. Next steps include optimizing the drug-like properties and oral availability of the compound.</p> <p>Takeda Pharmaceutical Co. Ltd. markets Velcade to treat multiple myeloma (MM) and mantle cell lymphoma (MCL).</p> <p>SciBX 7(2); doi:10.1038/scibx.2014.48 Published online Jan. 16, 2014</p>	Patent application filed; available for licensing	<p>Anchoori, R.K. <i>et al. Cancer Cell</i>; published online Dec. 9, 2013; doi:10.1016/j.ccr.2013.11.001</p> <p>Contact: Richard B.S. Roden, The Johns Hopkins University, Baltimore, Md. e-mail: roden@jhmi.edu</p>